Wan Bangde: The company's research on small molecule peptide new drugs is in the preclinical stage in fields such as obesity and diabetes.

On November 10, Vanbond stated on the interactive platform that the company's small molecule peptide new drug is currently in the preclinical stage in the fields of obesity, diabetes, and other indications, and has obtained good preliminary data. There are plans to advance clinical transformation. Compared with GLP-1 class drugs such as semaglutide, its target and mechanism of action are different. Preclinical data shows that it can both reduce weight, burn fat, reduce muscle loss, lower blood sugar, have anti-inflammatory effects, and improve multiple metabolic indicators. Especially in the study of diabetic obese mice, the efficiency of weight loss is significantly better than that of semaglutide.